## BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: 11/12, Sector E Sanwer Road, Indore-452015 (M.P.) Tel. 0731-2723016; Email id- bcplcompliance@gmail.com; Website- www.biofilgroup.net; Fax: 0731-2723017

Date: 22nd May, 2024

To,
The Secretary,
Corporate Relationship Department
The National Stock Exchange of India Limited
Bandra Kurla Complex, Mumbai

To,
The Secretary
Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers, 'A' wing
Dalal Street, Mumbai-400001

SUBJECT: Intimation for meeting of Board of the Directors (Serial No.01/2024-25) of the Company scheduled to be held on Thursday, 30<sup>th</sup> May, 2024 pursuant to the Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

REFERENCE: (BSE SCRIP CODE: 524396; NSE SYMBOL: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

With reference to above captioned subject and in terms of **Regulation 29 of the SEBI** (Listing Obligations and Disclosure Requirements) Regulation 2015, we are pleased to inform you that the meeting of the Board of Directors of the Company is scheduled to be held on **Thursday**, 30<sup>th</sup> May 2024, at Registered Office of the Company to transact the following matters:-

- 1. To Consider and Approve Audited Financial Results for the fourth Quarter as well as financial year ended on 31st March, 2024 along with Auditors Report thereon.
- 2. Other routine matters with the permission of the chair.

Further, we are submitting the above said information in XBRL mode along with the submission in PDF mode within prescribed time limit.

Further, in continuation to earlier disclosure dated 27th March, 2024, pursuant to Company's Code of Conduct to regulate, monitor and report trading in Company's Securities by Insiders framed under SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, Trading Window for dealing in the securities of the Company shall open after 48 hours of declaration of Audited Financial Results for

the fourth quarter and financial year ended  $31^{\rm st}$  March, 2024 for all designated persons, their immediate relatives and all connected persons covered under the aforesaid code.

You are requested to please take on record the above said information for your reference and further needful and disseminate on the website of the Exchange.

This is for your information and record.

Thanking you,

## FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

SHWETA VERMA
COMPANY SECRETARY & COMPLIANCE OFFICER
M. No. A70184